Open-label, randomized, controlled, comparative, cross-over study with 2 test sequences comparing a new 2-piece coupling system with SenSura Mio Click.

It will be a 1:1 randomization into the two possible treatment sequences

Each test period is 3 weeks (± 2 days), total study period is 6 weeks (± 4 days).

All visits will be performed as remote virtual calls. At the visits, the investigator will give instructions for the coming period and check that the trial is running as planned. At every bag change the subject will be asked to complete a questionnaire.

A follow-up call will be scheduled 7±1 days after each test visit to ensure compliance with the provided product and study procedures. Additional calls may be scheduled if needed.

Minimum 40 participants will be enrolled and randomized.

Inclusion Criteria:

1. Has given written consent to participate by signing the Informed Consent Signature Form
2. Be at least 18 years of age and have full legal capacity
3. Is able to handle (apply, remove, cut, etc.) the product and do the assessments themselves
4. Has an ileostomy or colostomy with consistent liquid fecal output (for colostomy: 6-7 Bristol stool scale)
5. Currently use SenSura Mio Click 2p Click flat or concave with 50 mm coupling size
6. Have had their ostomy for at least 90 days
7. Be willing to change the bag at least twice per week
8. Is willing and suitable (determined by the Principal Investigator or designee) to use flat or concave 2p open product during the investigation
9. Is willing to use 2p maxi open bags during the investigation

Exclusion Criteria:

1. Is currently receiving or have within the past 60 days received radio-and/or chemotherapy

   - Low doses radio- and/or chemotherapy (assessed by Principal Investigator) is allowed for indications other than cancer.

2. Is currently receiving or have within the past 30 days received topical steroid treatment in the peristomal skin area, e.g., lotion or spray

   • Low dose systemic steroid treatment (e.g., inhalation) assessed by the investigator are allowed.
   • Other systemic steroid treatment (e.g., injection or tablet) are not allowed.

3. Is pregnant and/or breast-feeding

4. Have a loop ileostomy

5. Is currently using convex baseplate

6. Has known hypersensitivity towards any of the products used in the investigation

Demographics are described for the total ITT population

Adverse events were collected over the study period of 6 weeks.

The investigation was non-blinded. However, the two products came from the same manufacturer and were very similar in appearance.

Subjects were instructed to register leakage through the coupling seen from the outside before opening the coupling. However, the accompanying instructive drawings showed leakage in an opened coupling, which could have resulted in overreporting of leakages that would only be visible after opening or happening when opening the coupling.